Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 30 results for clopidogrel

  1. Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]

    Discontinued [GID-TAG416]

  2. Bioresorbable stent implantation to treat coronary artery disease (IPG732)

    Evidence-based recommendations on bioresorbable stent implantation to treat coronary artery disease in adults. This involves implanting a stent (small tube) into a narrowed artery to widen it.

  3. Past appeals and decisions

    urothelial tract - vinflunine 23 May 2011 TA090 Vascular disease - clopidogrel and dipyridamole 25 February 2005 Back to top Rejected

  4. Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke (DG41)

    Evidence-based recommendations on implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke

  5. Heart valve disease presenting in adults: investigation and management (NG208)

    This guideline covers investigation and management of heart valve disease presenting in adults. It aims to improve quality of life and survival for people with heart valve disease through timely diagnosis and appropriate intervention.

  6. Transient ischaemic attack: clopidogrel (ESUOM23)

    This evidence summary has been withdrawn and NICE accredited guidance is available from the Royal College of Physicians.

  7. Head injury: assessment and early management (NG232)

    This guideline covers assessment and early management of head injury in babies, children, young people and adults. It aims to ensure that people have the right care for the severity of their head injury, including direct referral to specialist care if needed.

  8. Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome (TA80)

    This guidance has been replaced by recommendations 1.3.4 to 1.3.8 in NICE guideline CG94 and by recommendation 1.3.18 in NICE guideline CG172.

  9. ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)

    NICE has developed a medtech innovation briefing (MIB) on ClearWay RX for drug delivery to coronary artery thrombotic lesions

  10. Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events (TA90)

    This guideline has been updated and replaced by NICE technology appraisal 210.

  11. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (DG13)

    Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems)

  12. Type 2 diabetes in adults: management (NG28)

    This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.

  13. Research recommendations

    undergone revascularisation after an MI, does clopidogrel and placebo have a better outcome than clopidogrel and aspirin?...

  14. NICE launches second consultation on genetic testing to guide treatment after a stroke

    People could be offered a genetic test in the immediate period after having a stroke to help identify the most suitable treatment to reduce their risk of further strokes.

  15. Testing could help prevent further strokes in people with gene variant

    People who have had an ischaemic stroke or transient ischaemic attack should have a genetic test to find out whether they can be treated with a drug which reduces the risk of further strokes